ClinicalTrials.gg
RecruitingNCT06575101Updated Aug 12, 2026

Resting Energy Expenditure and Substrate Consumption in Cardiac Arrest Patients Under Target Temperature Management

An observational study in Targeted Temperature Management, Cardiac Arrest and Resting Energy Expenditure, sponsored by Tang Ziren. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Tang Ziren · Observational

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Heart Arrest with a site in China — 17 open to participants now, 22 under way, none of them phase 3. Heart Arrest · China.

Planned enrollment
22nd of 28
40 · median 300
Started
2024
with 3 others
Observational
28 of 37
13 open now
Primary completion
2028-12
later than 17 of 21 live
Registered
26th of 37
by date
Lead sponsor
5 of 37
Tang Ziren

Among the 37 studies in Heart Arrest with a site in China, this one is the 22nd largest by planned enrollment of the 28 observational ones that give a count, is one of 4 that started in 2024, is one of 28 observational ones, reaches primary completion later than 17 of the 21 other live ones, and was the 26th registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

17 of the 37 studies in Heart Arrest with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Heart Arrest with a site in China, or all of them as a file.
02

Study summary

This study is a single-center, prospective, observational study. According to the sample size formula, an estimated 40 cases should be collected, all of whom are from the emergency intensive care unit. After successful cardiopulmonary resuscitation, the enrolled patients will be transferred to the emergency intensive care unit for further standardized target temperature management (TTM). They will be divided into 33 ° C hypothermia group and 36 ° C hypothermia group according to the patient's core body temperature. The baseline data of the patients will be collected at the beginning. After admission to the hospital, they were fasted within 24 hours to reach the target temperature, and then 20kcal/kg/d parenteral nutrition will be given. At selected time points (T0: the initial time point before TTM; T1: the core temperature was reduced to 33 ° C or 36 ° C; T2-T4: 33 ° C or 36 ° C was maintained for 24h, 48h, 72h; T5: the end of rewarming; Tend: the last REE measurement before discharge or death) , various observation indicators will be collected, including resting energy expenditure (REE), glucose oxidation rate, fat oxidation rate, protein oxidation rate, and metabolism of three major nutrients Proportion. Neurological outcomes were followed up 28 days after onset according to the Cerebral Performance Categories (CPC) score.

03

Conditions studied

  • Targeted Temperature Management
  • Cardiac Arrest
  • Resting Energy Expenditure
  • Nutrition

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients(age >18 years) who have been successfully resuscitated from cardiac arrest who meet the inclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be admitted to the emergency department of Beijing Chao-yang Hospital, Capital Medical University;
  • Successfully resuscitated, and are unconscious after restoration of spontaneous circulation (ROSC);
  • Be admitted to the intensive care unit (ICU) for advanced life support such as endotracheal intubation after restoration of spontaneous circulation (ROSC);
  • Accepted target temperature management (TTM) therapy after restoration of spontaneous circulation (ROSC);

Exclusion criteria

Exclusion Criteria:

  • Age > 18 years old;
  • Incomplete clinical data and loss of follow-up;
  • Traumatic brain injury or cerebrovascular accident revealed by computed tomography (CT);
  • Severe metabolic abnormalities are known: cachexia, thyroid dysfunction, and cancer;
  • Indirect calorimetry measurement is not possible such as sustained oxygen concentration > 70%;
  • There were no signs of resuscitation at the time of admission;
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • 33℃ group

    Procedure: Target Temperature Management Treatment

  • 36℃ group

    Procedure: Target Temperature Management Treatment

Interventions

  • ProcedureTarget Temperature Management Treatment

    Target Temperature Management Treatment

06

What researchers measure

Primary outcomes

  1. Resting Energy Expenditure

    The primary outcome measure is the changes resting energy expenditure(REE) in the patients at various time points. patients at various time points.

    Time frame: 7 days

  2. Glucose oxidation rate

    The primary outcome measure is the statistical differences in Glucose oxidation rate between the two groups of patients at various time points.

    Time frame: 7 days

  3. Fat oxidation rate

    The primary outcome measure is the statistical differences in fat oxidation rate between the two groups of patients at various time points.

    Time frame: 7 days

  4. Protein oxidation rate

    The primary outcome measure is the statistical differences in protein oxidation rate between the two groups of patients at various time points.

    Time frame: 7 days

  5. Metabolic supply proportion of glucose, fat, protein

    The primary outcome measure is the statistical differences in metabolic supply proportion of glucose, fat, protein (measuring by indirect calorimetry) between the two groups of patients at various time points.

    Time frame: 7 days

Secondary outcomes

  1. CPC score

    CPC = Cerebral Performance Category Score.There are 5 levels of CPC score. CPC 1-2 means good prognosis of neurological function, CPC3-5 means bad prognosis of neurological function. The Secondary Outcome of the study is the statistical differences in the proportion of patients with good neurological outcome(CPC1-2) in the two groups at 28 days after CA.

    Time frame: 28 days

  2. Mortality rate

    The Secondary Outcome of the study is the statistical differences in the mortality rate of two groups at 28 days after CA.

    Time frame: 28 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Starting 6 months after publication

Access criteria: The identified survey data will be made available for research purposes by contacting the corresponding authors

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2028, 54 months after the start.

Of 169 non-industry observational studies under Heart Arrest, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 54 months is above that.

Counting every sponsor, half of 176 studies reached it within 41 months; a quarter within 18 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2024
First posted
Aug 28, 2024
StartActual
Jun 1, 2024
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06575101
Lead sponsor
Tang Ziren
Responsible party
Tang Ziren (Professor, Capital Medical University) — Sponsor-investigator
First posted
Aug 28, 2024
Start date
Jun 1, 2024
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Aug 12, 2026

Study contacts

Ziren Tang, MD
Contact
tangziren1970@163.com
010-85231530

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion